J
J. Grinyo
Researcher at Medical College of Wisconsin
Publications - 24
Citations - 955
J. Grinyo is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Belatacept & Kidney transplantation. The author has an hindex of 7, co-authored 24 publications receiving 792 citations. Previous affiliations of J. Grinyo include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Belatacept and Long-Term Outcomes in Kidney Transplantation.
Flavio Vincenti,Lionel Rostaing,J. Grinyo,Kim Rice,Steven M. Steinberg,Luis Gaite,Marie-Christine Moal,Guillermo A. Mondragon-Ramirez,Jatin Kothari,Martin Polinsky,Herwig Ulf Meier-Kriesche,Stephane Munier,Christian P. Larsen +12 more
TL;DR: Seven years after transplantation, patient and graft survival and the mean eGFR were significantly higher with belatacept (both the more-intensive and the less-intensive regimen) than with cyclosporine, and a 43% reduction in the risk of death or graft loss was observed.
Journal ArticleDOI
Multicenter Randomized Prospective Trial of Steroid Withdrawal in Renal Transplant Recipients Receiving Basiliximab, Cyclosporine Microemulsion and Mycophenolate Mofetil
TL;DR: Basiximab, a chimeric monoclonal interleukin-2 receptor antagonist, was studied for its effectiveness in allowing early corticosteroid withdrawal in de novo renal allograft recipients as mentioned in this paper.
Journal ArticleDOI
Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study
Antoine Durrbach,José Osmar Medina Pestana,Sander Florman,M. del Carmen Rial,Lionel Rostaing,Dirk Kuypers,Arthur J. Matas,Thomas Wekerle,Martin Polinsky,H. U. Meier-Kriesche,S. Munier,J. Grinyo +11 more
TL;DR: In this paper, a prospective analysis of the intent-to-treat population, efficacy and safety were compared across regimens at 7 years after transplant and the mean estimated GFR (eGFR) plus or minus standard error was 53.9 ± 1.9, 54.2 ± 1, and 35.3 ± 2.0 mL/min per 1.73 m2.
Symphony - Comparing Standard Immunosuppression to Low-Dose Cyclosporine, Tacrolimus or Sirolimus in Combination With Mmf, Daclizumab and Corticosteroids in Renal Transplantation
Henrik Ekberg,H. Tedesco Silva,A. Demirbas,Stefan Vitko,Bjoern Nashan,A. Gurkan,Raimund Margreiter,Christian Hugo,J. Grinyo,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +12 more
TL;DR: The low-dose TAC group was significantly superior to all other groups with respect to GFR and BPAR and to normaldose CsA and low- dose SRL for graft survival (pair-wise p<0.01).
Journal ArticleDOI
Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
Flavio Vincenti,Gilles Blancho,Antoine Durrbach,G. Grannas,J. Grinyo,H. U. Meier-Kriesche,Martin Polinsky,L. Yang,Christian P. Larsen +8 more
TL;DR: Although not statistically significant, rates of BPAR were 2‐fold higher in patients administered belatacept every 8 weeks vs every 4 weeks, and Renal function trends were estimated using a repeated‐measures model.